Mirna Therapeutics Inc. (MIRN) Trading Down 8.7%
Mirna Therapeutics Inc. (NASDAQ:MIRN)’s share price was down 8.7% on Thursday . The stock traded as low as $3.05 and last traded at $3.06, with a volume of 99,486 shares changing hands. The stock had previously closed at $3.35.
Several equities analysts recently weighed in on MIRN shares. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 price objective on shares of Mirna Therapeutics in a report on Friday, May 13th. Zacks Investment Research upgraded shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Thursday, July 14th. Leerink Swann lowered shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $10.00 to $4.00 in a report on Monday, August 15th. Citigroup Inc. lowered shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $7.00 to $4.50 in a report on Tuesday. Finally, Oppenheimer Holdings Inc. increased their price objective on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $8.10.
The company’s 50 day moving average is $4.18 and its 200 day moving average is $4.36. The stock’s market capitalization is $70.42 million.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.